Iron: The new advances in therapy

作者: Michael Auerbach , Lawrence Tim Goodnough , Aryeh Shander

DOI: 10.1016/J.BPA.2012.12.001

关键词:

摘要: Conditions known as iron-deficiency syndromes are very common in various patient populations, and they can adversely affect the outcomes of patients, addition to increasing their risk getting transfused. Iron-deficiency include absolute iron deficiency (absence storage iron), functional (when demand for exceeds supply face intense stimulation erythropoiesis) sequestration (in which existing becomes unavailable); these conditions often co-exist hospitalised making diagnosis management more difficult. Nonetheless, is emerging a safe effective therapy patients suffering from conditions. Notably, several intravenous formulations available be used safely effectively restore body levels (possibly even single treatment episode). Data ongoing clinical trials expected further establish role products with anaemia.

参考文章(80)
Robert S. Hillman, Perry A. Henderson, Control of marrow production by the level of iron supply Journal of Clinical Investigation. ,vol. 48, pp. 454- 460 ,(1969) , 10.1172/JCI106002
Ioannis E. Koutroubakis, Pantelis Oustamanolakis, Christos Karakoidas, Gerassimos J. Mantzaris, Elias A. Kouroumalis, Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Digestive Diseases and Sciences. ,vol. 55, pp. 2327- 2331 ,(2010) , 10.1007/S10620-009-1022-Y
David B. Van Wyck, Michael Roppolo, Carlos O. Martinez, Richard M. Mazey, Stephen Mcmurray, A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD Kidney International. ,vol. 68, pp. 2846- 2856 ,(2005) , 10.1111/J.1523-1755.2005.00758.X
Vaughn W Folkert, Beckie Michael, Rajiv Agarwal, Daniel W Coyne, Naomi Dahl, Pamela Myirski, David G Warnock, Ferrlecit® Publication Committee, Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥250 mg) administration * ** * American Journal of Kidney Diseases. ,vol. 41, pp. 651- 657 ,(2003) , 10.1053/AJKD.2003.50141
Elizabeta Nemeth, Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Advances in Hematology. ,vol. 2010, pp. 750643- 750643 ,(2010) , 10.1155/2010/750643
Durgesh Raje, Hasan Mukhtar, Ayo Oshowo, Celia Ingham Clark, What Proportion of Patients Referred to Secondary Care with Iron Deficiency Anemia Have Colon Cancer Diseases of The Colon & Rectum. ,vol. 50, pp. 1211- 1214 ,(2007) , 10.1007/S10350-007-0249-Y
Yalcin Solak, Huseyin Atalay, Ibrahim Guney, Kultigin Turkmen, Emine Kaya, Suleyman Turk, Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. Renal Failure. ,vol. 33, pp. 307- 311 ,(2011) , 10.3109/0886022X.2011.560404
Michael Auerbach, Jennifer A Pappadakis, Huzefa Bahrain, Sarah A Auerbach, Harold Ballard, Naomi V Dahl, None, Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia American Journal of Hematology. ,vol. 86, pp. 860- 862 ,(2011) , 10.1002/AJH.22153
Steven Fishbane, Virgiliu-Dan Ungureanu, John K. Maesaka, Charles J. Kaupke, Victoria Lim, Jay Wish, The safety of intravenous iron dextran in hemodialysis patients American Journal of Kidney Diseases. ,vol. 28, pp. 529- 534 ,(1996) , 10.1016/S0272-6386(96)90463-1
Michael Auerbach, Lawrence Tim Goodnough, Dan Picard, Alice Maniatis, The role of intravenous iron in anemia management and transfusion avoidance Transfusion. ,vol. 48, pp. 988- 1000 ,(2008) , 10.1111/J.1537-2995.2007.01633.X